AUAUniversity

Diagnosis and Management of Localized, Locally Advanced and Advanced Kidney Cancer (2022)

CME Available: https://auau.auanet.org/node/36089

LEARNING OBJECTIVES

At the conclusion of this course, participants will be able to:

1. Differentiate among the subtypes of kidney cancer, with emphasis on clinical management decisions, and outline ways in which knowledge of kidney cancer subtypes can alter surgical approach.

2. Apply advanced strategies for partial nephrectomy for patients with endophytic, hilar and multiple tumors including role of warm ischemia, intraoperative ultrasound, techniques for hemostatic control, the role of off-clamp and selective hilar clamping, the use of the retroperitoneal approach and methods for renorrhaphy.

3. Employ techniques for management of large and/or locally advanced tumors including management of renal vein or inferior vena cava invasion and the use of lymphadenectomy.

4. Identify the role of cytoreductive nephrectomy and/or resection of metastatic foci in patients with advanced disease.

5. Identify new and emerging targeted therapy and immuno-oncology options for patients with locally advanced and advanced kidney cancer and the role of adjuvant therapy.

Operationalizing Checkpoint Inhibitors in Urologic Practice (2022)

CME Available: https://auau.auanet.org/node/36084

LEARNING OBJECTIVES

At the conclusion of this course, participants will be able to:

1. Discuss how to develop a structured approach for administering checkpoint inhibitors in urologic practice as part of a structured program.

2. Manage adverse events from checkpoint inhibitors

3. Identify practice implications of implementing a checkpoint inhibitor program

Financial Toxicity as Drugs Move Earlier into Treatment Paradigm and How This Relates to Disparities in Treatment Patterns

CME Available: https://auau.auanet.org/node/35729

Moderator: Jay D. Raman, MD, FACS

Co-Hosts: Sarah Psutka, MD, MS

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

1. Define the magnitude of financial toxicity/economic implications across GU malignancies currently.

2. Forecast the potential changes/increases in financial burden associated with moving systemic therapies earlier in treatment paradigms for patients with GU malignancies.

ACKNOWLEDGEMENTS

Support provided by independent educational grants from:

Astellas

AstraZeneca

Bayer

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Merck & Co., Inc.

Pfizer, Inc.

Incorporating Genomic Testing for Prostate Cancer into Your Practice (2022)

CME Available: https://auau.auanet.org/node/36074

LEARNING OBJECTIVES

At the conclusion of this course, participants will be able to:

1. Discuss the research studies that led to the approval of genomic testing for prostate cancer

2. Order appropriate genomic testing based on a patient's unique clinical situation

3. State the NCCN and AUA guidelines for genomic testing for prostate cancer

4. Discern the different prognostic clinical endpoints provided by various genomic tests

5. Recognize candidates for, and implications of, germline testing for prostate cancer

Refractory Overactive Bladder: How to Select 3rd-Line Therapies and Optimize Outcomes (2022)

CME Available: https://auau.auanet.org/node/36033

LEARNING OBJECTIVES

At the conclusion of this course, participants will be able to:

1. Describe the various 3rd line therapies available to treat refractory overactive bladder (OAB) and be able to discuss the pros and cons of each of the 3rd line therapies available to treat refractory OAB.

2. Explain with the current data regarding outcomes of percutaneous tibial nerve stimulation (PTNS), onabotulinumtoxinA and sacral neuromodulation for treatment of refractory OAB.

3. Outline how to perform PTNS.

4. Report how to perform onabotunlinumtoxinA injections in the office or outpatient setting..

5. Review techniques in optimal lead placement for sacral neuromodulation, programming and troubleshooting.

Bladder Cancer Treatment Dilemmas: The Cases You Face and What To Do about Them (2022)

CME Available: https://auau.auanet.org/node/36049

LEARNING OBJECTIVES

At the conclusion of this course, participants will be able to:

1. Assign risk stratification to patients with bladder cancer.

2. Adapt treatment choices depending on risk of disease and availability of bacillus Calmette-Guérin (BCG).

3. Individualize patient surveillance needs.

4. Provide broadened treatment options beyond intravesical therapy.

Genetic Testing in Prostate Cancer: Clinical Implications for Early Detection and Management of Localized and Advanced Disease Webcast (2022)

CME Available: https://auau.auanet.org/node/36044

LEARNING OBJECTIVES

At the conclusion of this course, participants will be able to:

1. Counsel men with BRCA1/2 mutations, Lynch syndrome, and other key inherited syndromes regarding their prostate cancer risk and appropriate strategies for cancer screening.

2. Identify the criteria for genetic testing of prostate cancer patients, the gene panels available, and options for testing these men.

3. Interpret results of genetic testing and relay this information to patients in order to facilitate shared decision making based on the test results.

4. Utilize the results of genetic testing to improve outcomes among patients with metastatic prostate cancer, including recommendations regarding PARP-inhibition, chemotherapy, and immunotherapy.

CME Available: https://auau.auanet.org/node/35725

Moderator: Jay D. Raman, MD, FACS

Co-Hosts: Channa Amarasekera, MD; Simon Rosser, PhD, MPH

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

1. Identify two specific surgical side effects that may be of interest to a patient who undergoes a prostatectomy (e.g. ED treatment efficacy for anal penetration, climacturia, anejaculation).

2. Ask relevant questions about sexual practices that may impact the side effects that are of interest to them (partner with men, women and both and anal receptive vs. anal penetration sex).

ACKNOWLEDGEMENTS

Support provided by independent educational grants from:

Astellas

AstraZeneca

Bayer

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Merck & Co., Inc.

Pfizer, Inc.

Surgical & Medical Management of High-Risk Renal Cell Carcinoma: New Paradigms for Treatment(2022)

CME Available: https://auau.auanet.org/node/36065

LEARNING OBJECTIVES

At the conclusion of this course, participants will be able to:

1. Discuss new FDA approved checkpoint inhibitors for treatment and counseling of advanced renal cell carcinoma.

2. Identify indications, risks and benefit of neoadjuvant tyrosine kinase inhibitors for downsizing renal cell carcinoma.

3. Identify appropriate treatment options for management of complex cases.

Contemporary Pharmacotherapy for OAB 2022: Monotherapy and Combined Pharmacotherapy to Optimize Treatment (2022)

CME Available: https://auau.auanet.org/node/36028

LEARNING OBJECTIVES

At the conclusion of this course, participants will be able to:

1. Define the similarities and differences between the various oral pharmacotherapies for OAB.

2. Review the principles of physiology and pharmacotherapy for currently available agents, including the antimuscarinics and beta-3 agonists and combination therapy.

3. Explain the importance of setting proper patient expectations regarding treatment of OAB and the potential need for sequential and even additive therapies.

4. Analyze the clinical (and theoretical) advantages and limitations of currently available agents.

5. Discuss potential future pharmacological pathways and therapies for OAB.